DoD Previews Final Cybersecurity Maturity Model Certification with Revision 0.7
Client Alert | 1 min read | 12.17.19
The Department of Defense (DoD) recently released another revision to its Cybersecurity Maturity Model Certification (CMMC) that, starting next year, independent auditors will use to certify contractor compliance with DoD cybersecurity requirements. Most notably, Revision 0.7 previews the requirements for cybersecurity maturity Levels 4 and 5. Moving beyond the cyber hygiene requirements of Levels 1 through 3, Levels 4 and 5 require even more robust cybersecurity programs capable of addressing the dynamic threats posed by advanced persistent threats (APTs). These two highest levels of certification also implement the enhanced security requirements documented in NIST SP 800-171B, which remains in draft form.
The DoD is expected to announce the final CMMC in January of next year and begin introducing “go/no-go” certification requirements in solicitations as early as June 2020.
Contacts

Partner and Crowell Global Advisors Senior Director
- Washington, D.C.
- D | +1.202.624.2698
- Washington, D.C. (CGA)
- D | +1 202.624.2500
Insights
Client Alert | 4 min read | 09.16.26
CMS Offers Guidance as Scrutiny Rises Over ABA Therapy in Medicaid
Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy. In 2025, Medicaid spent about $10 billion on ABA and related therapy services for children with ASD — a dramatic increase from the $2 billion spent in 2021.
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
